Other
Sisters of the Third Order of St. Francis
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
Failure Rate
50.0%
1 terminated/withdrawn out of 2 trials
Success Rate
50.0%
-36.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 2
1(100.0%)
1Total
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT02462837Phase 2Terminated
Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement
Role: collaborator
NCT02410135Completed
Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)
Role: collaborator
All 2 trials loaded